Wanbang Pharmaceutical Holding Group (002082.SZ): The phase II/III clinical trial of Shishanjian Jia controlled release tablets has enrolled 100 subjects.

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Holding Group Pharmaceutical Group Co., Ltd., has completed the enrollment of 100 subjects for the phase II/III pivotal registration clinical trial of its new drug Shishang alkaloid methyl controlled-release tablets for the treatment of mild to moderate Alzheimer's disease dementia. Shishang alkaloid methyl is a cholinesterase inhibitor used to improve cognitive function. Preclinical studies have shown its potential to delay the progression of Alzheimer's disease, with a wide range of comprehensive benefits including reduction of beta-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects. It is expected to become a drug with broad-spectrum anti-Alzheimer's disease dementia properties. The company is actively enrolling subjects and will continue to work closely with over 50 national research institutions including the Xuanwu Hospital of Capital Medical University to further verify the safety and efficacy of the drug, providing crucial data support for the final market approval application.